Persist AI and Nivagen Collaborate on AI-Enhanced Manufacturing for Long-Acting Injectables

Persist AI and Nivagen have announced a strategic collaboration aimed at advancing the manufacturing process for long-acting injectable (LAI) drugs. This partnership seeks to combine Persist AI's expertise in AI-driven drug formulation with Nivagen's manufacturing capabilities to streamline the development and production of LAI drugs.

The collaboration focuses on developing a scalable manufacturing platform that leverages artificial intelligence to optimize drug release, stability, and bioavailability. This approach is expected to simplify the traditionally complex process of creating LAI drugs, which are designed to deliver medication over extended periods, ranging from weeks to months. By improving the efficiency and speed of LAI drug development, the collaboration aims to enhance patient adherence and outcomes, particularly in the treatment of chronic conditions.

See also: Ancient Material Promises To Solve Drug Delivery “Pain”

Karthik Raman, CEO of Persist AI, highlighted the potential impact of the partnership, emphasizing how the integration of AI technology could transform the treatment landscape for chronic diseases by making long-acting injectables more accessible and cost-effective.

Jay Shukla, CEO of Nivagen, echoed this sentiment:

"We are delighted to collaborate with Persist AI, a pioneer in AI-based formulation development for drug delivery systems. Our Sacramento, CA facility is equipped with robotic lines using Isolator technology to produce sterile drug products in IV bags (both aseptically and terminally sterilized), vials, syringes, and cartridges.  Persist's new technology will enhance our capabilities to handle complex injectables like long-acting injectables at our new manufacturing site. We believe that their technology can significantly reduce the time and cost of developing and producing long-acting injectables, which are a growing and underserved market. We look forward to combining our manufacturing capabilities and distribution network with their innovative technology to bring a new and differentiated product to market."

Persist AI, headquartered in West Sacramento, California, specializes in the development of drug delivery systems using AI-driven robotics. The company’s technology platform accelerates the optimization process for drug formulations, addressing unmet medical needs with innovative solutions.

Nivagen, based in Sacramento, California, is a specialty pharmaceutical company with a focus on developing, manufacturing, and distributing a wide range of pharmaceutical products, including generics and specialty drugs. Their state-of-the-art facility supports the production of various dosage forms and serves a global distribution network that reaches over 50 countries.

Topics: Manufacturing & Pharma 4.0